> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# REGENXBIO Chairman Kenneth Mills Resigns From Board After Taking CEO Job Elsewhere
- URL: https://www.bullished.co/regenxbio-chairman-kenneth-mills-resigns-from-board-after-taking-ceo-job-elsewhere-023eb9df/
- Published: 2026-10-16T11:05:51.000Z
- Updated: 2026-10-28T20:47:47.000Z
- Description: George Migausky, an independent director, becomes Chairman, and Daniel Tassé gives up the lead independent director role.
- Author: Matteo Parrino
- Tags: SEC Filings, RGNX, Industry: Healthcare

REGENXBIO Chairman Kenneth T. Mills [resigned from the board](https://www.sec.gov/Archives/edgar/data/0001590877/000119312526423376/rgnx-20261014.htm?ref=bullished.co) on Wednesday, effective October 21, 2026, after becoming chief executive of another company, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) the company filed Friday. The board named director George Migausky to succeed him as Chairman.

## What the 8-K says

The filing, made under the item covering departures of directors and officers, says Mills recently became chief executive officer of another company and intends to focus his efforts on that role. It does not name the company.

The filing also says his decision was not related to any disagreement with [REGENXBIO](https://www.bullished.co/tag/rgnx/) on any matter relating to its operations, policies, or practices.

Mills told the company of his resignation on Wednesday, the date of the event reported. The 8-K itself is dated Friday, October 16, 2026, and is signed by Patrick J. Christmas II, the company's Executive Vice President, Chief Strategy & Legal Officer.

## What changes on the board

In connection with Mills' departure, the board appointed Migausky as Chairman. The filing describes him as an independent director.

That status triggers a second change. Under the company's Corporate Governance Guidelines, Daniel Tassé has stepped down as Lead Independent Director because the new Chairman is independent. Tassé stays on the board.

The filing does not describe any other change to the board's makeup.

## The stock and the next date

REGENXBIO shares closed at $7.16 at Thursday's close, up 4.07% on the session, before the filing appeared Friday morning. That move came before the news, so it is not a reaction to it.

Mills' resignation takes effect October 21, 2026.

Mills' departure becomes effective October 21, 2026, with Migausky as Chairman and Tassé still on the board.

Learn

- [Item 5.02: directors and officers leave or join, or executive pay is set →](https://www.bullished.co/learn/8-k-items-explained/#item-502-directors-and-officers-leave-or-join-or-executive-pay-is-set)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — REGENXBIO Inc. (RGNX)](https://www.sec.gov/Archives/edgar/data/0001590877/000119312526423376/rgnx-20261014.htm?ref=bullished.co) — SEC EDGAR

### More on REGENXBIO

- [JPMorgan Reports 5.3% Passive Stake In REGENXBIO, 3,560,915 Shares, In SEC Filing](https://www.bullished.co/jpmorgan-reports-5-3-passive-stake-in-regenxbio-3-560-915-shares-in-sec-filing-af469bd6/)

[All REGENXBIO (RGNX) coverage →](https://www.bullished.co/tag/rgnx/)